EV/DNG (Qlaira, BAY86-5027, SH T00658K) + EV/DNG (SH T00658L)
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Ovulation Inhibition
Conditions
Ovulation Inhibition
Trial Timeline
Mar 1, 2003 → Feb 1, 2004
NCT ID
NCT00805415About EV/DNG (Qlaira, BAY86-5027, SH T00658K) + EV/DNG (SH T00658L)
EV/DNG (Qlaira, BAY86-5027, SH T00658K) + EV/DNG (SH T00658L) is a phase 2 stage product being developed by Bayer for Ovulation Inhibition. The current trial status is completed. This product is registered under clinical trial identifier NCT00805415. Target conditions include Ovulation Inhibition.
What happened to similar drugs?
3 of 5 similar drugs in Ovulation Inhibition were approved
Approved (3) Terminated (2) Active (2)
🔄SHR7280；Ganirelix Acetate Injection simulant + SHR7280 simulant； Ganirelix Acetate InjectionJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
12
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00805415 | Phase 2 | Completed |
Competing Products
13 competing products in Ovulation Inhibition